GlaxoSmithKline PLC (NYSE:GSK) – Jefferies Group issued their Q3 2016 EPS estimates for shares of GlaxoSmithKline PLC in a report issued on Thursday. Jefferies Group analyst J. Holford anticipates that the brokerage will earn $0.72 per share for the quarter. Jefferies Group currently has a “Buy” rating on the stock.

Earnings History and Estimates for GlaxoSmithKline PLC (NYSE:GSK)

Several other brokerages have also recently issued reports on GSK. Citigroup Inc. restated a “buy” rating on shares of GlaxoSmithKline PLC in a report on Wednesday, July 27th. HSBC restated a “buy” rating on shares of GlaxoSmithKline PLC in a report on Monday, September 12th. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “hold” rating in a report on Monday, July 25th. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline PLC in a report on Wednesday, August 17th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, September 22nd. Three analysts have rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $47.86.

Shares of GlaxoSmithKline PLC (NYSE:GSK) opened at 41.68 on Friday. The company has a market cap of $101.30 billion, a PE ratio of 2605.00 and a beta of 0.89. The firm’s 50-day moving average is $43.15 and its 200-day moving average is $42.93. GlaxoSmithKline PLC has a one year low of $37.82 and a one year high of $45.58.

The business also recently declared a dividend, which was paid on Thursday, October 13th. Shareholders of record on Friday, August 12th were issued a $0.494 dividend. The ex-dividend date was Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio is currently 6,166.67%.

A number of hedge funds have recently made changes to their positions in GSK. Hamlin Capital Management LLC boosted its position in shares of GlaxoSmithKline PLC by 0.6% in the second quarter. Hamlin Capital Management LLC now owns 1,463,148 shares of the pharmaceutical company’s stock worth $63,413,000 after buying an additional 9,117 shares during the last quarter. Confluence Investment Management LLC boosted its position in shares of GlaxoSmithKline PLC by 12.4% in the second quarter. Confluence Investment Management LLC now owns 1,330,992 shares of the pharmaceutical company’s stock worth $57,685,000 after buying an additional 146,825 shares during the last quarter. Aviance Capital Management LLC boosted its position in shares of GlaxoSmithKline PLC by 67.3% in the second quarter. Aviance Capital Management LLC now owns 877,233 shares of the pharmaceutical company’s stock worth $38,019,000 after buying an additional 352,748 shares during the last quarter. GW&K Investment Management LLC boosted its position in shares of GlaxoSmithKline PLC by 7.1% in the second quarter. GW&K Investment Management LLC now owns 745,241 shares of the pharmaceutical company’s stock worth $32,299,000 after buying an additional 49,267 shares during the last quarter. Finally, Union Bankshares Corp acquired a new position in shares of GlaxoSmithKline PLC during the second quarter worth approximately $208,000. Institutional investors own 8.79% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.